Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,767 | $1,912 | $1,261 | $1,779 |
| - Cash | $4,810 | $795 | $1,798 | $2,435 |
| + Debt | $0 | $0 | $112 | $222 |
| Enterprise Value | -$3,042 | $1,117 | -$425 | -$433 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$872 | -$964 | -$1,718 | -$1,488 |
| % Margin | – | – | – | – |
| Net Income | -$873 | -$958 | -$1,710 | -$1,464 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.81 | -6.75 | -15.45 | -22.8 |
| % Growth | 73.2% | 56.3% | 32.2% | – |
| Operating Cash Flow | -$1,647 | -$862 | -$1,182 | -$743 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,647 | -$862 | -$1,182 | -$743 |